Combined anti-PD1 immunotherapy for patient with advanced pancreatic cancer: A case report

Zhe Jiang, Hongyan Li, Fei Li
{"title":"Combined anti-PD1 immunotherapy for patient with advanced pancreatic cancer: A case report","authors":"Zhe Jiang, Hongyan Li, Fei Li","doi":"10.36922/td.v1i1.52","DOIUrl":null,"url":null,"abstract":"Pancreatic cancer (PC) is a highly lethal malignancy with a dismal 5-year survival rate. The current treatment modalities for the treatment-associated toxicity of immunotherapy-based approaches are limited. Immunotherapy for PC was needed to be further investigated. This report illustrates the combined use of anti PD-1 immunotherapy with other therapeutic strategies for cancer pain. In this case, a patient with PC was treated with surgical resection, chemotherapy, molecular targeted medicine, and anti-PD1 immunotherapy. The survival period of the patient was more than 6 years since diagnosis. Finally, we will present our perspective on the future development of immunotherapy for PC. In a word, this case report sheds lights on information that would be helpful for more rigorous exploration of PC treatments.","PeriodicalId":94260,"journal":{"name":"Tumor discovery","volume":"70 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumor discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36922/td.v1i1.52","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Pancreatic cancer (PC) is a highly lethal malignancy with a dismal 5-year survival rate. The current treatment modalities for the treatment-associated toxicity of immunotherapy-based approaches are limited. Immunotherapy for PC was needed to be further investigated. This report illustrates the combined use of anti PD-1 immunotherapy with other therapeutic strategies for cancer pain. In this case, a patient with PC was treated with surgical resection, chemotherapy, molecular targeted medicine, and anti-PD1 immunotherapy. The survival period of the patient was more than 6 years since diagnosis. Finally, we will present our perspective on the future development of immunotherapy for PC. In a word, this case report sheds lights on information that would be helpful for more rigorous exploration of PC treatments.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
联合抗pd1免疫治疗晚期胰腺癌1例报告
胰腺癌(PC)是一种高致死率的恶性肿瘤,其5年生存率很低。目前基于免疫疗法的治疗相关毒性的治疗方式是有限的。PC的免疫治疗有待进一步研究。本报告阐述了联合使用抗PD-1免疫疗法与其他治疗策略的癌症疼痛。本例PC患者接受手术切除、化疗、分子靶向药物和抗pd1免疫治疗。自诊断以来,患者生存期超过6年。最后,我们将对PC免疫治疗的未来发展提出展望。总之,本病例报告提供的信息将有助于更严格地探索PC治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Matrix metalloproteinase-1 as a potential biomarker for early gastric cancer detection and its effect on gastric cancer cell proliferation and migration Bioinformatics analysis of missense mutations in CXCR1 implicates altered protein stability and function Profiling energy metabolism in normal bladder tissue and non-muscle-invasive bladder cancer cases of different histological grades Odontogenic myxofibroma arising in the mandibular angle of a child with long-term follow-up: A case report Artificial intelligence enabled spatially resolved transcriptomics reveal spatial tissue organization of multiple tumors
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1